48% discontinuation among weight loss GLP-1 users 33% discontinuation among diabetes GLP-1 users Discontinuation of GLP-1 therapy is associated with metabolic rebound, including weight regain, rising blood pressure, and worsening glycemic control, undermining both clinical outcomes and the value of initial investment
The phase 2 BELIEVE trial of bimagrumab plus semaglutide versus bimagrumab monotherapy may have the answer
Our comprehensive portfolio includes APIs, Finished Formulations, Veterinary Medicines, Herbal Products, and Nutraceuticals, along with a wide range of therapeutic segments making us your reliable one-stop global pharma partner.
Which Semaglutide Is Most Effective
Patients agree to follow dietary and lifestyle recommendations and understand that long-term success depends on more than medication alone
Common Mistakes about GLP-1 Side Effects Mistake 1: Treating every side effect as equally likely